To read the full story, subscribe or sign in.

Teva ties up agreement with Alvotech to commercialize five biosimilars

Aug. 11, 2020

HONG KONG – Tel Aviv-based Teva Pharmaceutical Industries Ltd. has inked an exclusive strategic agreement with Reykjavik, Iceland-based Alvotech hf to commercialize five biosimilar product candidates in the U.S.

BioWorld Asia Deals and M&A

Today's news in brief

BioWorld

BioWorld briefs for Jan. 27, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for January 27, 2025

Illustration of cell receptors, antibodies

Abbvie and Simcere enter a $1B T-cell engager deal

BioWorld Asia

Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the 43rd annual J.P. Morgan Healthcare...

Scanning electron micrograph of M. tuberculosis

In monkeys, enhanced TB vaccine dissolves after inducing protection

BioWorld Science

An experimental tuberculosis (TB) vaccine with a dual mission – self-destruction after inducing immunity – improved the design of the Bacillus Calmette-Guérin...

New drugs with the same old resistance tricks?

BioWorld

According to the World Health Organization (WHO), multidrug-resistant pathogens caused over 1.27 million deaths worldwide in 2020. And figures are rising, with...